← All trials
NCT06227949
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 29, 2024
- Primary completion
- Dec 31, 2029
- Completion date
- Dec 31, 2031
- First posted
- Jan 29, 2024
- Last posted
- Jan 29, 2024
- Enrollment
- 140
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of TorontoLead sponsor
- Merck SeronoCollaborator
- University of TorontoSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.